Lindahl served as advisor to Orexo AB (publ) when it acquired the exclusive rights from GAIA AG to distribute the digital therapy tool deprexis® in the United States.
deprexis® is a fully automated therapy developed by GAIA. It provides the user with personalised cognitive behavioural therapy interventions for managing symptoms of depression. The effectiveness of deprexis® has been evaluated and published in 13 randomised clinical trials that have included more than 2,500 patients. Orexo and GAIA expect that the COVID-19 crisis and the actions taken to control the pandemic will result in a significant rise in mental illness, such as depression, and consequently an increased need for digital therapies. Orexo is aiming to launch deprexis® on the US market during the summer of 2020. The annual net sales potential of deprexis® is expected to exceed USD 150 m – 225 million. At the time of writing, deprexis® has already been launched in multiple countries globally.
Orexo develops pharmaceuticals and digital therapies that meet an important need, particularly in the treatment of abuse and addiction. The products are commercialised independently in the USA or through partners worldwide. The main market for buprenorphine/naloxone products is currently the American market, where Orexo commercialises its lead product Zubsolv® for treatment of opioid use disorder. In 2019, the company’s total net sales reached SEK 845 million and it had 127 employees. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the USA. The company’s head office is in Uppsala, Sweden, where it conducts its research and development activities.
The law firm Lindahl has served as legal advisor to Orexo and the team has comprised Patrik Rindstål (responsible partner) and Mikael Olsson (GDPR).
